Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
The availability of mesenchymal stem cells (MSCs) or skeletal stem cells (SSCs) is vital to many of the tissue engineering strategies currently being developed for repairing bone and cartilage. One difficulty with using this cell population is that SSCs represent only a small fraction of the cells available from an individual patient's bone marrow sample, typically less than 1 in 10,000. Therefore, methods have been devised to enrich the proportion of MSCs obtained from a bone marrow sample using hybridoma cell lines to generate antibodies to cell surface antigens specific for MSCs. Stro-1 is the most widely targeted of these cell surface antigens. The protocol described overleaf is used to isolate and enrich the Stro-1 positive fraction of cells from a bone marrow aspirate to provide a sample enriched for MSCs for use in both in vitro and in vivo studies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/978-1-62703-508-8_7 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!